Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASSURE long-term open-label seladelpar safety study in primary biliary cholangitis
NL-OMON51913Phase 3Recruiting
- Sponsor
- CymaBay Therapeutics
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of seladelpar in primary biliary cholangitis (PBC), sponsored by CymaBay Therapeutics. Primary endpoints: Treatment-emergent adverse events and Biochemistry and hematology results. Started Nov 2021; status: recruiting.
02
Drugs
seladelpar
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NL-OMON51913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51913.